Sava

Sava is a London company developing a continuous glucose monitor built on a microsensor worn just under the skin, with a filament roughly a tenth the length of a conventional CGM's, which measures glucose and other molecules in interstitial fluid in real time. In February 2026 it reported world-first 10-day clinical evidence from 46 participants with type 1 or insulin-dependent type 2 diabetes at Oxford and Cambridge sites. The company describes the sensor as still an experimental device: it has no MHRA or FDA approval, and commercial availability is targeted for 2027 subject to clearance. Ascensia Diabetes Care led its October 2026 Series B and holds an exclusive agreement to distribute the microsensor, starting in Europe.